Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Roche Holdings Ltd ADR (RHHBY)
Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 274,975,776
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 69,608 M
  • Annual Income, $ 13,016 M
  • 60-Month Beta 0.41
  • Price/Sales 3.91
  • Price/Cash Flow 12.83
  • Price/Book 8.11
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/02/23
  • Annual Dividend & Yield 0.80 (2.01%)
  • Most Recent Dividend 0.802 on 03/16/23
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.4100 +4.82%
on 04/27/23
40.3300 -0.17%
on 05/26/23
+1.5800 (+4.08%)
since 04/26/23
3-Month
34.7000 +16.02%
on 03/28/23
40.3300 -0.17%
on 05/26/23
+3.4500 (+9.37%)
since 02/24/23
52-Week
34.7000 +16.02%
on 03/28/23
43.3200 -7.06%
on 11/11/22
-3.0700 (-7.09%)
since 05/26/22

Most Recent Stories

More News
Why Shares of Rain Oncology Are Plummeting Today

The company released disappointing top-line results for its lead oncology therapy.

RAIN : 1.1000 (-3.51%)
RHHBY : 40.2600 (+0.90%)
Roche introduces navify® Sample Tracking for labs to track patient test samples before even reaching lab premises

At Worldlab-EuroMedLab, Roche presents navify® Sample Tracking, a digital solution allowing labs to connect to innovative applications that monitor quality and...

RHHBY : 40.2600 (+0.90%)
Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will be showcasing innovative laboratory solutions and digital diagnostics through -...

RHHBY : 40.2600 (+0.90%)
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.

RHHBY : 40.2600 (+0.90%)
SRPT : 126.82 (-1.58%)
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

RHHBY : 40.2600 (+0.90%)
JNJ : 154.35 (-0.04%)
HALO : 33.20 (+0.18%)
OCUP : 3.89 (+7.16%)
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

RHHBY : 40.2600 (+0.90%)
BMY : 63.82 (-1.15%)
NVO : 162.97 (+0.33%)
PRTA : 66.44 (-1.20%)
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

RHHBY : 40.2600 (+0.90%)
ADMA : 4.08 (+3.55%)
BPMC : 57.75 (+6.39%)
APTX : 0.0714 (-0.83%)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

REGN : 725.05 (+0.01%)
RHHBY : 40.2600 (+0.90%)
SNY : 52.51 (-0.15%)
UNH : 481.52 (+0.80%)
JNJ : 154.35 (-0.04%)
XLV : 127.53 (-0.20%)
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

REGN : 725.05 (+0.01%)
SNY : 52.51 (-0.15%)
RHHBY : 40.2600 (+0.90%)
BAYRY : 14.5900 (+1.96%)
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.

RHHBY : 40.2600 (+0.90%)
LGND : 72.13 (+0.63%)
SRPT : 126.82 (-1.58%)
ALLO : 5.53 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 40.6967
2nd Resistance Point 40.5133
1st Resistance Point 40.3867
Last Price 40.2600
1st Support Level 40.0767
2nd Support Level 39.8933
3rd Support Level 39.7667

See More

52-Week High 43.3200
Last Price 40.2600
Fibonacci 61.8% 40.0272
Fibonacci 50% 39.0100
Fibonacci 38.2% 37.9928
52-Week Low 34.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar